Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo

Gene Therapy

Volumn 17, Issue 1, 2010, Pages 72-82

  Kutzler, M A ^a   Kraynyak, K A ^b   Nagle, S J ^b   Parkinson, R M ^b   Zharikova, D ^c   Chattergoon, M ^d   Maguire, H ^b   Muthumani, K ^b   Ugen, K ^e,f   Weiner, D B ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WISTAR INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

DNA vaccines; Immune modulation; Immune responses; Molecular adjuvants

Indexed keywords

ANTIBODY; CHEMOKINE; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL28 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; IMMUNOMODULATION; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS A; INTESTINE LYMPHATIC TISSUE; LUNG PARENCHYMA; MORBIDITY; MORTALITY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; PROTEIN BLOOD LEVEL; QUADRICEPS FEMORIS MUSCLE; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMOKINE CCL27; CHEMOKINES, CC; IMMUNIZATION; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INTERFERON-GAMMA; MICE; PLASMIDS; VACCINES, DNA;

MUS;

EID: 74349122577     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.112     Document Type: Article

References (51)

1. Schoenly KA, Weiner DB. HIV-1 vaccine development: recent advances in the CTL platform 'spotty business'. J Virol 2008; 82: 3166-3180.
2. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9: 776-788.
3. Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. Vaccine 2000; 18: 2592-2599.
4. Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 2005; 175: 112-123.
5. Chattergoon MA, Saulino V, Shames JP, Stein J, Montaner LJ, Weiner DB. Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. Vaccine 2004; 22: 1744-1750.
6. Chattergoon MA, Kim JJ, Yang JS, Robinson TM, Lee DJ, Dentchev T et al. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol 2000; 18: 974-979.
7. Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 2004; 202: 266-274.
8. Lori F, Weiner DB, Calarota SA, Kelly LM, Lisziewicz J. Cytokine-adjuvanted HIV-DNA vaccination strategies. Springer Semin Immunopathol 2006; 28: 231-238.
9. Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 2006; 12: 216-222.
10. Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006; 40: 86-97.
11. Hokey DA, Weiner DB. DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol 2006; 28: 267-279.
12. Lee S, Gierynska M, Eo SK, Kuklin N, Rouse BT. Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus. Microbes Infect 2003; 5: 571-578.
13. Kaneko H, Bednarek I, Wierzbicki A, Kiszka I, Dmochowski M, Wasik TJ et al. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 2000; 267: 8-16.
14. Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000; 164: 3102-3111.
15. Biragyn A, Belyakov IM, Chow YH, Dimitrov DS, Berzofsky JA, Kwak LW. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemo-attractants induce systemic and mucosal immune responses. Blood 2002; 100: 1153-1159.
16. Bagarazzi ML, Boyer JD, Javadian MA, Chattergoon MA, Shah AR, Cohen AD et al. Systemic and mucosal immunity is elicited after both intramuscular and intravaginal delivery of human immunodeficiency virus type 1 DNA plasmid vaccines to pregnant chimpanzees. J Infect Dis 1999; 180: 1351-1355.
17. Wang B, Dang K, Agadjanyan MG, Srikantan V, Li F, Ugen KE et al. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine 1997; 15: 821-825.
18. Liu MA, Wahren B, Karlsson Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 2006; 17: 1051-1061.
19. Dhama K, Mahendran M, Gupta PK, Rai A. DNA vaccines and their applications in veterinary practice: current perspectives. Vet Res Commun 2008; 32: 341-356.
20. Bergman PJ. Canine oral melanoma. Clin Tech Small Anim Pract 2007; 22: 55-60.
21. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007; 196: 1732-1740.
22. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv Genet 2005; 55: 25-40.
23. McKay PF, Barouch DH, Santra S, Sumida SM, Jackson SS, Gorgone DA et al. Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur J Immunol 2004; 34: 1011-1020.
24. Kutzler MA, Weiner DB. Developing DNA vaccines that call to dendritic cells. J Clin Invest 2004; 114: 1241-1244.
25. Boyer JD, Kim J, Ugen K, Cohen AD, Ahn L, Schumann K et al. HIV-1 DNA vaccines and chemokines. Vaccine 1999; 17 (Suppl 2): S53-S64.
26. Sin J, Kim JJ, Pachuk C, Satishchandran C, Weiner DB. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol 2000; 74: 11173-11180.
27. Kim JJ, Yang JS, Dentchev T, Dang K, Weiner DB. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J Interferon Cytokine Res 2000; 20: 487-498.
28. Morales J, Homey B, Vicari AP, Hudak S, Oldham E, Hedrick J et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA 1999; 96: 14470-14475.
29. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002; 16: 1-4.
30. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001; 194: 1541-1547.
31. Soler D, Humphreys TL, Spinola SM, Campbell JJ. CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood 2003; 101: 1677-1682.
32. Lazarus NH, Kunkel EJ, Johnston B, Wilson E, Youngman KR, Butcher EC. A common mucosal chemokine (mucosae-asso-ciated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J Immunol 2003; 170: 3799-3805.
33. Pan J, Kunkel EJ, Gosslar U, Lazarus N, Langdon P, Broadwell K et al. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues. J Immunol 2000; 165: 2943-2949.
34. Feng N, Jaimes MC, Lazarus NH, Monak D, Zhang C, Butcher EC et al. Redundant role of chemokines CCL25/TECK and CCL28/MEC in IgA+ plasmablast recruitment to the intestinal lamina propria after rotavirus infection. J Immunol 2006; 176: 5749-5759.
35. Hieshima K, Kawasaki Y, Hanamoto H, Nakayama T, Nagakubo D, Kanamaru A et al. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J Immunol 2004; 173: 3668-3675.
36. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003; 170: 1136-1140.
37. Morteau O, Gerard C, Lu B, Ghiran S, Rits M, Fujiwara Y et al. An indispensable role for the chemokine receptor CCR10 in IgA antibody-secreting cell accumulation. J Immunol 2008; 181: 6309-6315.
38. Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 2004; 199: 84-99.
39. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000; 68: 793-806.
40. Xu R, Megati S, Roopchand V, Luckay A, Masood A, Garcia-Hand D et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 2008; 26: 4819-4829.
41. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8: 157-165.
42. Loetscher P, Seitz M, Baggiolini M, Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 1996; 184: 569-577.
43. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998; 28: 2760-2769.
44. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997; 277: 2005-2007.
45. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002; 283: R7-R28.
46. Lukacs NW. Migration of helper T-lymphocyte subsets into inflamed tissues. J Allergy Clin Immunol 2000; 106: S264-S269.
47. Robinson HL, Boyle CA, Feltquate DM, Morin MJ, Santoro JC, Webster RG. DNA immunization for influenza virus: studies using hemagglutinin-and nucleoprotein-expressing DNAs. J Infect Dis 1997; 176 (Suppl 1): S50-S55.
48. Kim JJ, Nottingham LK, Sin JI, Tsai A, Morrison L, Oh J et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 1998; 102: 1112-1124.
49. Ogawa T, Tarkowski A, McGhee ML, Moldoveanu Z, Mestecky J, Hirsch HZ et al. Analysis of human IgG and IgA subclass antibody-secreting cells from localized chronic inflammatory tissue. J Immunol 1989; 142: 1150-1158.
50. Mestecky J, Jackson S, Moldoveanu Z, Nesbit LR, Kulhavy R, Prince SJ et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses 2004; 20: 972-988.
51. Mozdzanowska K, Feng J, Eid M, Zharikova D, Gerhard W. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 2006; 352: 418-426.